Actively Recruiting
Observational Study to Identify Barriers to Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Newly Diagnosed and Relapsed Acute Leukemia, Myelodysplastic Syndrome, and Myeloproliferative Neoplasms
Led by Memorial Sloan Kettering Cancer Center · Updated on 2026-01-20
1365
Participants Needed
3
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are studying patients with newly diagnosed or relapsed acute leukemia, myelodysplastic syndrome (MDS), and myeloproliferative neoplasms (MPN) to understand how many receive allogeneic hematopoietic stem cell transplantation (HCT) and why some do not proceed with this treatment when recommended. The study also explores reasons behind patients' decisions to decline transplantation. This observational research aims to identify barriers to HCT in these blood cancers and includes patients with post-transplant relapse. Participants are divided into three groups: those with acute leukemia (Arm A), those with MDS or MPN (Arm B), and those with acute leukemia or MDS/MPN who relapse after first allografts (Arm C). Patients are followed throughout their treatment journey to prospectively identify reasons why they may not proceed to HCT despite eligibility and physician recommendation. Standard laboratory assessments, including HLA allele typing, are performed as part of routine care. During the study, patients undergo regular monitoring with standard laboratory tests and assessments. Researchers track who proceeds to transplant over a three-year period as the main outcome measure. The study observes patients' clinical progress and treatment decisions without administering experimental treatments. Participation may last several years to fully capture transplant outcomes and reasons for non-progression.
CONDITIONS
Brief Title
Identify Barriers to Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Newly Diagnosed and Relapsed Acute Leukemia
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with newly diagnosed or relapsed acute leukemia, including those undergoing reinduction due to primary induction failure
- Patients diagnosed with MDS, MPN, or MDS/MPN overlap meeting criteria such as cytopenia affecting at least two cell lines, bone marrow blasts over 5%, evidence of disease progression, or specific risk scores
- Patients with acute leukemia or MDS/MPN who relapse after first allografts
- Patients aged 18 to 80 years
- Definition of relapse includes re-emergence of abnormal myeloid blast population comprising 5% or more of marrow WBC or any amount prompting therapeutic intervention
You will not qualify if you...
- Patients diagnosed with polycythemia vera (PV)
- Patients diagnosed with essential thrombocytosis (ET)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Up to 3 years
Participants who meet eligibility criteria are followed throughout their clinical journey to identify reasons why they may not proceed to hematopoietic stem cell transplantation when deemed appropriate and eligible.
Trial Site Locations
Total: 3 locations
1
Hartford Healthcare Cancer Institute @ Hartford Hospital
Hartford, Connecticut, United States, 06102
Actively Recruiting
2
Memorial Sloan Kettering Cancer Center
New York, New York, United States, 10065
Actively Recruiting
3
Lehigh Valley Health Network
Allentown, Pennsylvania, United States, 18103
Active, Not Recruiting
Research Team
R
Roni Tamari, MD
S
Sergio Giralt, MD
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
3
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here